Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs

Journal of Gastrointestinal Oncology

Volumn 5, Issue 4, 2014, Pages 247-252

  Peixoto, Renata D'Alpino ^a   Noonan, Krista L ^a   Pavlovich, Peter ^a   Kennecke, Hagen F ^a   Lim, Howard J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Carcinoid tumors; Carcinomas; Chemotherapy; Pancreatic endocrine tumors; Pancreatic neuroendocrine tumors (PNETs)

Indexed keywords

CAPECITABINE; KI 67 ANTIGEN; TEMOZOLOMIDE;

ADULT; AGED; APPENDIX TUMOR; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; INTESTINE TUMOR; LUNG TUMOR; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RECTUM TUMOR; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR LOCALIZATION;

EID: 84995745354     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2014.019     Document Type: Article

References (18)

1. Hauser H, Wolf G, Uranu¨s S, et al. Neuroendocrine tumours in various organ systems in a ten-year period. Eur J Surg Oncol 1995;21:297-300.
2. Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987;14:343-53.
3. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
4. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
5. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-52.
6. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6.
7. Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012;30:2963-8.
8. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75.
9. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858-68.
10. Medley L, Morel AN, Farrugia D, et al. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 2011;104:1067-70.
11. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-45.
12. Fine RL, Gulati AP, Tsushima D, et al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. J Clin Oncol 2014;32:abstr 179.
13. Fine RL, Fogelman DR, Schreibman MS. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. J Clin Oncol 2005;23:abstr 4216.
14. Murakami J, Lee YJ, Kokeguchi S, et al. Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep 2007;17:1461-7.
15. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-45.
16. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
17. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
18. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.